

Medicines Optimisation Advice Bulletin – July 2024

For the attention of primary and secondary care staff involved in patient care

Fezolinetant for treating vasomotor symptoms associated with the menopause

Key Message

There should be **no prescribing** of Fezolinetant in primary or secondary care

NICE are currently appraising the use of Fezolinetant in the NHS for treating vasomotor symptoms associated with the menopause. There is not currently a date for publication - [Project information | Fezolinetant for treating vasomotor symptoms associated with the menopause \[ID5071\] | Guidance | NICE](#)

Once NICE publish their recommendation, it will progress through the Norfolk and Waveney ICB commissioning process. This will involve a formulary application to identify estimated patient numbers, position in treatment pathway and confirmation of prescribing responsibility.

As this will likely be a NICE Technology Appraisal, we will have 90 days from date of publication to commission and ensure availability of this treatment for prescribers and patients.

Until then, there should be **no prescribing** of Fezolinetant in primary or secondary care.

Once commissioned, it will be added to Netformulary and the TAG guidance. Prescribers will be notified via the usual communication channels.

Please email the medicines optimisation team with 'TAG' in the subject line if you have any further questions or comments - nwicb.medsqueries@nhs.net.

Many thanks for your support.

Sent on behalf of the Norfolk and Waveney Therapeutics Advisory Group